Last week, Brigham and Women's Hospital announced that it would pioneer a trial using a spray drug for Alzheimer's disease.

Alzheimer's treatments were not considered likely just months ago.

Alzheimer's treatments seemed like an unlikely prospect just months ago.

A recently approved medication for Alzheimer’s disease is making headlines because of its price tag. It costs $56,000 a year.

Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.

Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.